Shattuck labs, inc.STTK.US Overview

US StockHealthcare

(No presentation for STTK)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

STTK Overall Performance

STTK AI Analysis & Strategy

STTK Recent Performance

3.24%

Shattuck labs, inc.

0.81%

Avg of Sector

-1.14%

S&P500

STTK PowerScanner

STTK Key Information

STTK Valuation Metrics

STTK Earnings Table

STTK Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.